Pharmaceuticals

Citius Pharma

Citius Pharma released FY2025 Q4 earnings on December 23 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4627 (forecast USD -0.43)

Citius Pharma released FY2025 Annual Earnings on December 23 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.383 (forecast USD -3.125)

Citius Pharma released FY2025 Q3 earnings on August 12 (EST), actual revenue USD 0 (forecast USD 1.919 M), actual EPS USD -0.8 (forecast USD -0.21)

Citius Pharma released FY2025 9 Months Earnings on August 12, 2025 (EST), with actual revenue USD 0 and EPS USD -3.3744

Citius Pharmaceuticals Inc to report a loss of 59 cents per share

Citius Pharmaceuticals, Inc. Expected to Reach Break-even in 2025

Citius Pharmaceuticals Completes Registered Direct Offering

Citius Pharmaceuticals Inc. Secures $6 Million Prepayment and Up to $9.8 Million Warrant Proceeds

Citius Pharmaceuticals Shareholders Approve Increase in Stock Numbers

Citius Pharma released FY2025 Semi-Annual Earnings on May 14 (EST) with actual revenue of USD 0 and EPS of USD -2.5759

Citius Pharma released FY2025 Q2 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2721 (forecast USD -0.3833)

Citius Pharmaceuticals Inc Expects to Report EPS of 33 Cents in May 12, 2025

Citius Pharmaceuticals Inc. Announces Public Offering of Common Stock at $1.15 to Raise $2 Million

Citius Pharma released FY2025 Q1 earnings on February 14 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.3037 USD (forecast -1.365 USD)

Boral Capital Upgrades Citius Pharma Rating to Buy with Target Price of $9.00

Citius Pharma released FY2024 Q4 earnings on December 27 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.5918 (forecast USD -1.5266)

Citius Pharma released FY2024 annual earnings on December 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -5.9738 USD (forecast -5.8033 USD)

FDA Approves Citius Pharmaceuticals' Blood Cancer Therapy Lymphir

Xindi Pharmaceuticals' antibiotic lock solution Mino-Lok achieves positive results in Phase III study for catheter-related bloodstream infections

Citius Pharmaceuticals' milestone in the second half of 2024

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap